Your browser is no longer supported. Please, upgrade your browser.
RETA Reata Pharmaceuticals, Inc. daily Stock Chart
RETA [NASD]
Reata Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-9.35 Insider Own1.10% Shs Outstand32.99M Perf Week20.80%
Market Cap4.95B Forward P/E- EPS next Y-7.84 Insider Trans-7.86% Shs Float26.44M Perf Month-20.51%
Income-290.20M PEG- EPS next Q-2.01 Inst Own81.20% Short Float11.28% Perf Quarter-31.17%
Sales26.50M P/S186.72 EPS this Y-228.10% Inst Trans17.75% Short Ratio7.26 Perf Half Y69.00%
Book/sh8.12 P/B18.47 EPS next Y10.10% ROA-73.80% Target Price297.25 Perf Year77.86%
Cash/sh20.14 P/C7.45 EPS next 5Y- ROE-766.90% 52W Range70.00 - 257.96 Perf YTD-26.63%
Dividend- P/FCF- EPS past 5Y- ROI-45.40% 52W High-39.41% Beta2.58
Dividend %- Quick Ratio3.50 Sales past 5Y-12.60% Gross Margin- 52W Low123.27% ATR17.85
Employees220 Current Ratio3.50 Sales Q/Q-68.20% Oper. Margin- RSI (14)48.33 Volatility13.07% 12.42%
OptionableYes Debt/Eq1.45 EPS Q/Q-586.80% Profit Margin- Rel Volume0.46 Prev Close149.99
ShortableYes LT Debt/Eq0.86 EarningsFeb 19 AMC Payout- Avg Volume410.57K Price156.29
Recom1.40 SMA20-1.35% SMA50-18.52% SMA2004.87% Volume109,322 Change4.20%
Nov-13-19Downgrade National Securities Buy → Neutral
Sep-26-19Initiated National Securities Buy $130
Sep-25-18Reiterated Leerink Partners Outperform $116 → $139
Sep-13-17Initiated Leerink Partners Outperform $43
Jul-25-17Reiterated Citigroup Buy $39 → $87
Apr-13-17Initiated Ladenburg Thalmann Buy $55
Feb-23-17Initiated Stifel Buy $38
Jan-25-17Initiated Robert W. Baird Outperform $43
Jun-20-16Initiated Piper Jaffray Overweight $33
Jun-20-16Initiated Citigroup Buy
Mar-22-20 08:30PM  Hedge Funds Have Never Been This Bullish On Reata Pharmaceuticals, Inc. (RETA) Insider Monkey
Mar-20-20 11:30AM  Reata Pharmaceuticals, Inc. (RETA) Down 37.8% Since Last Earnings Report: Can It Rebound? Zacks -10.84%
Feb-27-20 03:09AM  Edited Transcript of RETA earnings conference call or presentation 19-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-19-20 04:01PM  Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financials and Provides an Update on Development Programs GlobeNewswire
Feb-12-20 04:01PM  Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2019 Financials and to Provide an Update on Development Programs on February 19, 2020 GlobeNewswire
Feb-04-20 11:28AM  Vanguard Health Care Fund Adds 4 Stocks to Portfolio in 4th Quarter GuruFocus.com
Jan-31-20 04:41PM  How A Rumored Amgen Takeover Sent This Biotech Stock Flying Investor's Business Daily +12.76%
01:22PM  Reata Pharma Soars on Amgen Takeover Rumor TheStreet.com
Jan-17-20 05:40PM  Pharma and Biotech Arent Worried About Democratic Candidates Attacks Against Drugmakers Barrons.com
Dec-15-19 05:59AM  3 Monster Growth Stocks Racing to New Highs TipRanks
Dec-09-19 09:52AM  Hedge Funds Have Never Been This Bullish On Reata Pharmaceuticals, Inc. (RETA) Insider Monkey
Dec-04-19 08:20PM  Edited Transcript of RETA earnings conference call or presentation 12-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-25-19 03:00PM  Plano-based pharma company expects to double headcount as it raises $505M in stock sale American City Business Journals
Nov-18-19 11:15AM  Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Nov-15-19 12:54PM  Reata Pharmaceuticals, Inc. Analysts Are Pretty Bullish On The Stock After Recent Results Simply Wall St.
Nov-13-19 07:15PM  Reata Pharmaceuticals, Inc. Announces Pricing of Upsized Class A Common Stock Public Offering GlobeNewswire
Nov-12-19 04:01PM  Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock GlobeNewswire -14.43%
07:55AM  Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:20AM  The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat Benzinga
06:45AM  Reata Pharmaceuticals, Inc. Announces Third Quarter 2019 Financial Results and an Update on Development Programs GlobeNewswire
Nov-11-19 05:15PM  This Biotech Has Rocketed 181% Since October Did It Just Tap Out? Investor's Business Daily
04:23PM  Reata Pharma kidney drug meets study goals, stock halted MarketWatch
04:02PM  Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome GlobeNewswire
Nov-05-19 06:45AM  Reata Pharmaceuticals, Inc. to Report Third Quarter 2019 Financial Results and to Provide an Update on Development Programs on November 12, 2019 GlobeNewswire
Oct-30-19 10:33AM  Earnings Preview: Reata Pharmaceuticals, Inc. (RETA) Q3 Earnings Expected to Decline Zacks
Oct-29-19 01:37PM  Reata Pharmaceuticals, Inc. (RETA): These Hedge Funds Sold Prior To Large Gains Insider Monkey
Oct-20-19 08:08AM  The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict Benzinga
Oct-17-19 08:58AM  Reata (RETA) Jumps: Stock Rises 5. 6% Zacks
Oct-16-19 07:06AM  The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch Benzinga +5.60%
05:03AM  Riding 2 Big Winners in Small Biotech TheStreet.com
Oct-15-19 05:13PM  Reata Successfully Completes Neuromuscular Disorder Study Zacks +56.99%
04:13PM  How A Recently Reacquired Drug Added $1.8 Billion To This Biotech's Value Investor's Business Daily
01:13PM  A Look At Benzinga Pro's Most-Searched Tickers For October 15, 2019 Benzinga
10:10AM  Reata Pharmaceuticals Options Hot as Shares Skyrocket Schaeffer's Investment Research
07:50AM  The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings Benzinga
Oct-14-19 04:36PM  Reata stock jumps 30% as neuromuscular disorder drug meets study endpoint MarketWatch
04:01PM  Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreichs Ataxia GlobeNewswire
01:52PM  [video]Reata Shares Jump on Drug-Study Results TheStreet.com
Oct-11-19 10:00AM  Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019 GlobeNewswire +11.43%
Oct-10-19 04:18PM  Why This Biotech Stock Was Bullish Enough To Relicense Its Own Drugs Investor's Business Daily +13.00%
07:31AM  The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO Benzinga
06:45AM  Reata Pharmaceuticals Reacquires Rights From AbbVie to Develop and Commercialize Bardoxolone Methyl, Omaveloxolone, and All Next-Generation Nrf2 Activators GlobeNewswire
Oct-01-19 07:22AM  Is Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) CEO Pay Fair? Simply Wall St. -5.98%
Sep-11-19 10:02AM  Is the Options Market Predicting a Spike in Reata Pharmaceuticals (RETA) Stock? Zacks
Sep-06-19 09:40AM  Is Reata Pharmaceuticals (NASDAQ:RETA) Using Debt Sensibly? Simply Wall St.
Sep-02-19 03:09PM  Edited Transcript of RETA earnings conference call or presentation 8-Aug-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-29-19 07:38AM  The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings Benzinga +6.53%
Aug-28-19 04:01PM  Reata Appoints Manmeet S. Soni as Chief Financial Officer; Jason D. Wilson to Assume New Role as EVP, Operations GlobeNewswire
Aug-12-19 01:47AM  Reata Pharmaceuticals, Inc. (RETA) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 07:55AM  Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:40AM  Reata Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results and an Update on Development Programs GlobeNewswire
Aug-01-19 11:49AM  Is Reata Pharmaceuticals, Inc.'s (NASDAQ:RETA) CEO Paid At A Competitive Rate? Simply Wall St.
06:45AM  Reata Pharmaceuticals, Inc. to Report Second Quarter 2019 Financials and to Provide an Update on Development Programs on August 8, 2019 GlobeNewswire
Jun-17-19 10:27AM  The Reata Pharmaceuticals (NASDAQ:RETA) Share Price Has Soared 359%, Delighting Many Shareholders Simply Wall St.
Jun-11-19 04:36PM  Hedge Funds Have Never Been This Bullish On Reata Pharmaceuticals, Inc. (RETA) Insider Monkey
Jun-06-19 10:29AM  Reata's (RETA) Kidney Candidate Gets Orphan Drug Status Zacks
07:37AM  The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering Benzinga
Jun-05-19 06:00PM  Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease GlobeNewswire
Jun-04-19 07:00PM  Reata Announces Presentations at the 56th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) GlobeNewswire
May-30-19 06:45AM  Reata Announces First Patient Enrolled in Phase 3 FALCON Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease GlobeNewswire
May-23-19 01:47AM  Edited Transcript of RETA earnings conference call or presentation 9-May-19 12:00pm GMT Thomson Reuters StreetEvents -5.30%
May-22-19 12:46PM  Reata's drug, Bardoxolone, shows promising results for chronic kidney disease Yahoo Finance Video
May-09-19 08:23PM  Reata Pharmaceuticals, Inc. (RETA) Q1 2019 Earnings Call Transcript Motley Fool
07:55AM  Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Lags Revenue Estimates Zacks
06:45AM  Reata Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results and an Update on Development Programs GlobeNewswire
May-06-19 03:26PM  Biotech developing kidney disease treatment jumps after hedge fund recommendation at conference CNBC +5.77%
May-02-19 04:15PM  Reata Announces Presentation at the Annual CKD3 Chronic Kidney Disease Drug Development Summit GlobeNewswire
06:45AM  Reata Pharmaceuticals, Inc. to Report First Quarter 2019 Financials and to Provide an Update on Development Programs on May 9, 2019 GlobeNewswire
May-01-19 12:45PM  Did Hedge Funds Drop The Ball On Reata Pharmaceuticals, Inc. (RETA) ? Insider Monkey
Apr-30-19 07:52AM  Reata Pharmaceuticals, Inc. (NASDAQ:RETA): When Will It Breakeven? Simply Wall St.
Apr-02-19 03:20PM  Reata CEO on drug that shows signs of reversing kidney damage CNBC Videos +7.29%
Mar-15-19 11:43AM  Edited Transcript of RETA earnings conference call or presentation 28-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
Feb-28-19 11:56AM  Reata Pharmaceuticals, Inc. (RETA) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:45AM  Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2018 Financials and Operating Results GlobeNewswire
Feb-25-19 12:59PM  Who Has Been Buying Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Shares? Simply Wall St.
Feb-22-19 10:30AM  Analysts Estimate Reata Pharmaceuticals, Inc. (RETA) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-21-19 06:45AM  Reata Pharmaceuticals, Inc. to Report Fourth Quarter and Full Year 2018 Financials and to Provide an Update on Development Programs GlobeNewswire
Feb-20-19 06:45AM  Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in Patients with Focal Segmental Glomerulosclerosis and in Patients From All Four Cohorts of PHOENIX GlobeNewswire
Feb-05-19 07:45AM  Analysis: Positioning to Benefit within LPL Financial, The Andersons, Del Frisco's Restaurant Group, United Fire Group, Reata Pharmaceuticals, and Federal Agricultural Mortgage Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-07-19 07:15AM  Reata Pharmaceuticals, Inc. Appoints Geoffrey A. Block, M.D. as Vice President, Nephrology GlobeNewswire +23.24%
Jan-04-19 09:02AM  2 Promising Biotech Stocks That Insiders Are Snapping Up TheStreet.com +13.74%
Jan-03-19 04:01PM  Reata Announces Clinical Trial Design for FALCON, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease GlobeNewswire -6.87%
Dec-19-18 01:17AM  Reata Pharmaceuticals, Inc. (RETA): Hedge Funds Are Snapping Up Insider Monkey
Nov-26-18 08:55AM  Report: Exploring Fundamental Drivers Behind Reata Pharmaceuticals, Calyxt, SIFCO Industries, EchoStar, Tel-Instrument Electronics, and United States Antimony New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +6.68%
Nov-19-18 05:53PM  Edited Transcript of RETA earnings conference call or presentation 7-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-07-18 11:20AM  Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Lags Revenue Estimates Zacks +13.41%
07:00AM  Reata Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results and an Update on Development Programs GlobeNewswire
Oct-31-18 04:35PM  Reata Pharmaceuticals, Inc. to Report Third Quarter 2018 Financial Results and Provide an Update on Development Programs on Wednesday, November 7, 2018 GlobeNewswire
Oct-16-18 07:05AM  Reata Announces Presentation of Four Clinical Abstracts at the American Society of Nephrology Kidney Week 2018 GlobeNewswire
Oct-09-18 07:40AM  Research Report Identifies Cerner, Reata Pharmaceuticals, Lennar, Acacia Communications, GoPro, and ProAssurance with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Sep-25-18 07:00AM  Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in IgA Nephropathy and Type 1 Diabetic Chronic Kidney Disease GlobeNewswire
Sep-21-18 08:58AM  Is the Options Market Predicting a Spike in Reata Pharmaceuticals (RETA) Stock? Zacks
Sep-18-18 08:24AM  Who Just Ramped Up Their Shares In Reata Pharmaceuticals Inc (NASDAQ:RETA)? Simply Wall St.
Aug-30-18 06:40PM  Reata Announces Receipt of $30 Million Milestone Payment From Kyowa Hakko Kirin GlobeNewswire
Aug-22-18 11:41AM  Edited Transcript of RETA earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-18 08:05PM  Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM  Reata Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results and an Update on Development Programs GlobeNewswire
Aug-06-18 05:35PM  Reata Pharmaceuticals, Inc. to Report Second Quarter 2018 Financial Results and an Update on Development Programs on Wednesday, August 8, 2018 GlobeNewswire
Jul-28-18 08:38AM  3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys? Motley Fool
Jul-27-18 11:05AM  Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Castellanos ElaineVP, Chief Accounting OfficerMar 02Sale194.322,000388,64015,146Mar 02 03:02 PM
Wilson Jason DouglasExecutive VP of OperationsDec 16Sale203.2610,0002,032,59112,950Dec 17 05:30 PM
Castellanos ElaineVP, Chief Accounting OfficerDec 02Sale194.242,000388,48015,146Dec 03 04:03 PM
ROSE WILLIAMMember of 10% owner groupNov 20Sale212.536,5911,400,77119,795Dec 05 05:22 PM
ROSE WILLIAMMember of 10% owner groupNov 19Sale210.002,000420,00026,386Dec 05 05:22 PM
Traweek James W JR10% OwnerNov 18Buy183.0040,2187,359,8943,063,567Nov 18 05:23 PM
McGaughy R Kent JrDirectorNov 18Buy183.0040,2187,359,8943,063,567Nov 18 05:21 PM
CPMG IncDirectorNov 18Buy183.0040,2187,359,894282,246Nov 18 05:20 PM
ROSE WILLIAMMember of 10% owner groupNov 18Sale202.041,000202,04028,386Dec 05 05:22 PM
Castellanos ElaineVP, Chief Accounting OfficerOct 28Sale200.004,000800,00015,146Oct 30 11:32 AM
Castellanos ElaineVP, Chief Accounting OfficerOct 25Sale190.002,000380,00015,146Oct 28 04:41 PM
Castellanos ElainePrincipal Accounting OfficerOct 18Sale170.002,000340,00011,933Oct 21 03:32 PM
Wilson Jason DouglasExecutive VP of OperationsOct 17Sale170.0010,0001,700,0007,350Oct 21 03:39 PM
Castellanos ElainePrincipal Accounting OfficerOct 15Sale147.5914,0002,066,24011,933Oct 17 04:51 PM
Wilson Jason DouglasExecutive VP of OperationsOct 15Sale146.1315,0002,191,9567,350Oct 15 04:03 PM
Wilson Jason DouglasExecutive VP of OperationsOct 14Sale100.0015,0001,500,0007,350Oct 15 04:03 PM
Castellanos ElainePrincipal Accounting OfficerOct 14Sale105.003,000315,00011,933Oct 15 03:52 PM
Huff James WarrenChief Executive OfficerSep 27Sale86.6163,0005,456,11594,157Sep 30 03:18 PM
Castellanos ElainePrincipal Accounting OfficerSep 06Sale85.002,000170,0002,138Sep 10 03:46 PM
Wilson Jason DouglasChief Financial OfficerAug 15Sale72.684,000290,7350Aug 16 03:09 PM
Wilson Jason DouglasChief Financial OfficerJul 15Sale84.644,000338,5560Jul 17 01:01 PM
Wilson Jason DouglasChief Financial OfficerJun 17Sale83.544,000334,1770Jun 19 04:06 PM
Castellanos ElainePrincipal Accounting OfficerJun 03Sale85.202,000170,4002,138Jun 05 01:10 PM
Wilson Jason DouglasChief Financial OfficerMay 15Sale89.914,000359,6310May 17 11:47 AM
Wilson Jason DouglasChief Financial OfficerApr 15Sale83.824,000335,2620Apr 16 02:21 PM
Castellanos ElainePrincipal Accounting OfficerApr 08Sale90.172,000180,3402,138Apr 09 05:24 PM